Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

SQZ Biotechnologies Co (SQZ) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Cost Associated with Exit or Disposal Activities, Material Impairments, Departure of Directors or Certain Officers; Election ...
07/25/2023 8-K Quarterly results
07/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/03/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ...
01/18/2023 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
09/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SQZ Biotechnologies Announces Leadership Transition Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company’s Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering WATERTOWN, Mass., September 6, 2022 –"
07/11/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
01/24/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
12/09/2021 8-K Quarterly results
12/02/2021 8-K Quarterly results
11/18/2021 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/26/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate into Combination with Checkpoint Inhibitors High Dose Monotherapy Cohort Clinical Data from the SQZ-PBMC-HPV-101 Trial Accepted for Oral Presentation at ESMO IO in December Cohorts in Combination with anti-PD-1 and anti-CTLA-4 Open for Enrollment Combination Stage Initiation Triggers Milestone Payment from Roche WATERTOWN, Mass., October 26, 2021"
09/13/2021 8-K Quarterly results
09/02/2021 8-K Quarterly results
07/29/2021 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience Bernard Coulie, M.D., Ph.D. and Patrick Vink, M.D. Join Board of Directors"
06/17/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/09/2021 8-K Results of Operations and Financial Condition
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : February 9, 2021 SQZ BIOTECHNOLOGIES COMPANY Delaware 001-39662 46-2431115 200 Arsenal Yards Blvd, Suite 210 Watertown, MA 02472 758-8672 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 ..."
11/04/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : November 3, 2020 SQZ BIOTECHNOLOGIES COMPANY Delaware 001-39662 46-2431115 200 Arsenal Yards Blvd, Suite 210 Watertown, MA 02472 758-8672 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4...",
"Restated Certificate of Incorporation of SQZ Biotechnologies Company"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy